G1 THERAPEUTICS, INC. 2017 ANNUAL REPORT

LETTER FROM THE CEO

Dear Fellow Shareholders:

I am pleased to provide an update on our first year as a public company. We have an exciting opportunity to improve the lives of people living with cancer and we thank you for supporting that mission. Our pipeline currently consists of three drug candidates that are designed to address significant unmet medical needs and represent multi-billion dollar markets.

1. **Trilaciclib**: a potential first-in-class short-acting intravenous CDK4/6 inhibitor in development to preserve hematopoietic stem cells and enhance immune system function (myelopreservation) during chemotherapy.
2. **G1T38**: a potential best-in-class oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications.
3. **G1T48**: a potential first- / best-in-class oral selective estrogen receptor degrader (SERD) being developed for the treatment of ER+ breast cancer.

Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as the backbone of multiple combination regimens. G1T48, as monotherapy or in combination with G1T38, could provide a new treatment option for women with ER+ breast cancer.

In 2017 and early 2018, we achieved multiple milestones that laid the groundwork for our future growth. Highlights included:

- Reported encouraging preliminary trilaciclib Phase 1b trial results in first-line small cell lung cancer (SCLC). These data, which were presented at ASCO 2017, provided the rationale for the Phase 2a trial that completed enrollment in 2017.
- Announced positive topline results from the trilaciclib Phase 2a trial in first-line SCLC in March of 2018.
- Fully enrolled the Phase 2 trial evaluating trilaciclib in combination with chemotherapy and Tecentriq® (atezolizumab) in first-line SCLC.
- Initiated two G1T38 Phase 1/2 trials: one in combination with Faslodex® (fulvestrant) in ER+, HER2- breast cancer, and the other in combination with Tagrisso® (osimertinib) in EGFR-mutant non-small cell lung cancer (NSCLC).
- Submitted the G1T48 Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for treatment of ER+ breast cancer.
- Forged non-exclusive clinical collaborations with Genentech and AstraZeneca.
- Added key senior leadership in Finance, Regulatory Affairs, Development Operations and Clinical Development, and strengthened our Board of Directors with the addition of Sir Andrew Witty.
- Executed a successful financing to provide operating capital into 2020.

These achievements have positioned us to realize multiple value inflection points in 2018, including:

- Presenting data from our successful trilaciclib Phase 2a trial in first-line SCLC.
- Announcing preliminary data from the trilaciclib Phase 2 trials in both second- / third-line SCLC and triple negative breast cancer (TNBC).
- Initiating meetings with U.S. and European health authorities to discuss the regulatory pathway for trilaciclib.
- Presenting preliminary data from the Phase 1b portion of the G1T38 trial in ER+, HER2- breast cancer.
- Initiating the first clinical trial of G1T48, which will evaluate the therapy in ER+, HER2- breast cancer.

We look forward to sharing updates as we continue to advance our innovative pipeline and build a valuable enterprise.

Mark Velleca, M.D., Ph.D.
Chief Executive Officer